ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 969
Modulation of Cartilage Degradation Biomarkers Reflect the Activation and Inhibition of Pro-Inflammatory Cytokine Signaling in an Ex Vivo Model of Bovine Cartilage
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?
9:00AM-11:00AM
Abstract Number: 1708
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II
9:00AM-11:00AM
Abstract Number: 1019
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Genetics, Genomics and Proteomics Poster II
9:00AM-11:00AM
Abstract Number: 1427
Monitoring of Absolute Lymphocyte Count in Patients with Rheumatoid Arthritis Treated with Tofacitinib
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 1579
Monocyte-Derived Dendritic Cells (MDDCs) from Spondyloarthritis (SpA) Patients Exhbit a Coordinated Downregulation of the Cholesterol (chol) Biosynthesis Pathway That Relates to Lipid Overload
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 1570
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 968
Mononuclear Phagocytes Mediate Systemic Autoimmune Disease-Related Valvular Heart Disease Via Inflammatory Cytokine Production and Recruitment of Tissue-Reparative macrophages
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?
9:00AM-11:00AM
Abstract Number: 1591
Monophasic Disease Course Pattern in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1504
More Than 10 Percent Patients with Recent Onset Chronic Mechanical Back Pain Fulfill the Modified NY Criteria for Sacroiliitis
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II
9:00AM-11:00AM
Abstract Number: 1333
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Rheumatoid Arthritis – Animal Models Poster II
9:00AM-11:00AM
Abstract Number: 1008
mtDNA Cybrids from OA Patients Are Less Efficient Using Glycolysis and Are More Susceptible to Apoptosis Under Stress Conditions
Genetics, Genomics and Proteomics Poster II
9:00AM-11:00AM
Abstract Number: 1746
mTOR Pathway Activation in Takayasu Arteriti
T Cell Biology and Targets in Autoimmune Disease Poster I
9:00AM-11:00AM
Abstract Number: 1065
Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway
Innate Immunity and Rheumatic Disease Poster II
9:00AM-11:00AM
Abstract Number: 1180
Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
9:00AM-11:00AM
Abstract Number: 1072
Mutated Peptidylarginine Deiminase from Porphyromonas Gingivalis Is a Target in Rheumatoid Arthritis and Citrullinates Major RA-Autoantigens
Innate Immunity and Rheumatic Disease Poster II
  • «Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology